Related Experiment Video
Updated: Jul 13, 2026
Porcine Corneal Tissue Explant to Study the Efficacy of Herpes Simplex Virus-1 Antivirals
Published on: September 20, 2021
Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination
S Shimoyama1, F Goshima, O Teshigahara
1Department of Surgery II, Graduate School of Medicine Nagoya University, Nagoya, Japan.
Background/Aims:
Oncolytic viral therapy is used worldwide. Many genetically engineered viruses have been evaluated for their potential as a new therapeutic agent for cancer. HF10, herpes simplex virus (HSV) type-1 clone, has remarkable anti-tumor effects, based on our previous research. In this study, we investigated the ability of HF10 to infect and lyse murine colon cancer cells, CT26, in vitro, and tested its efficacy in an immuno-competent animal model of colorectal cancer. Further, we attempted to evaluate HF10/paclitaxel combination therapy.
Methodology:
In vitro, viral replication and cytotoxicity of HF10 against CT26 was observed. In vivo, BALB/c mice harboring carcinomatous peritonitis of CT26 cells were treated with HF10, paclitaxel or HF10 combined with paclitaxel.
Results:
HF10 is effective for peritoneal dissemination without ascites. The combination of HF10 and paclitaxel prolonged survival of mice bearing carcinomatous dissemination of CT26 compared with the controls, HF10 alone and paclitaxel alone. Paclitaxel did not suppress viral replication and cytotoxicity of HF10.
Conclusions:
These results indicate that the combination of HF10 and paclitaxel had a remarkable effect as a cancer therapy and this method is applicable to almost all advanced cancers. This new combination therapy is a potentially epoch-making cancer therapy.
Insights
Oncolytic virus HF10 combined with paclitaxel significantly improved survival in a colorectal cancer model. This combination therapy shows promise for advanced cancers, without hindering viral activity.
Area of Science:
- Oncology
- Virology
- Cancer Therapy
Background:
- Oncolytic viral therapy is a growing field utilizing genetically engineered viruses for cancer treatment.
- Herpes simplex virus (HSV) type-1 clone HF10 demonstrates significant anti-tumor effects.
- Previous research supports HF10's potential as a therapeutic agent.
Purpose of the Study:
- To evaluate HF10's efficacy in infecting and lysing murine colon cancer cells (CT26) in vitro.
- To test HF10's effectiveness in an immunocompetent animal model of colorectal cancer.
- To assess the combination therapy of HF10 and paclitaxel for colorectal cancer.
Main Methods:
- In vitro analysis of HF10 viral replication and cytotoxicity against CT26 cells.
- In vivo study using BALB/c mice with CT26 cell-induced carcinomatous peritonitis.
- Treatment groups included HF10 alone, paclitaxel alone, and the combination of HF10 and paclitaxel.
Main Results:
- HF10 demonstrated effectiveness against peritoneal dissemination of colon cancer cells.
- The combination of HF10 and paclitaxel significantly prolonged survival in mice compared to monotherapies.
- Paclitaxel did not inhibit the viral replication or cytotoxicity of HF10.
Conclusions:
- The combination of HF10 and paclitaxel exhibits a remarkable therapeutic effect for cancer.
- This novel combination therapy is potentially applicable to a wide range of advanced cancers.
- This approach represents a potentially groundbreaking advancement in cancer treatment.
